Focused on discovery and development of therapeutic fusion proteins based on its proprietary Elastin-Like Polypeptide (ELP) technology

Sectors
Healthcare
Life Sciences
First Invested
2009
Early
Company Status
IPO/Public
NASDAQ: PHAS